Pharmaceutical Care of a Patient with Dermatomyositis and Pulmonary Infection Caused by Fluconazole and Thalidomide
Objective To investigate the role of clinical pharmacists in pharmaceutical care in the treatment of patients with dermatomyositis and pulmonary infection.Methods A clinical pharmacist participated in the drug treatment of one case of dermatomyositis and pulmonary infection,analyzed the causes of adverse drug reactions in the patient,and provided pharmaceutical care.Results The clinical pharmacist suggested that the suspicious drug thalidomide should be stopped after the onset of numbness in limbs and lip numbness,which was adopted by the physician.However,the patients′s numbness in limbs and lip did not improve significantly,and the clinical pharmacist once again suggested that the suspicious drug fluconazole should be stopped,and the patient′s numbness in limbs and lip improved.Conclusion The participation of clinical pharmacists in the formulation of treatment plan and the provision of pharmaceutical care can help to improve the therapeutic effect and promote rational drug use.Meanwhile,it is suggested that patients who used thalidomide should be closely monitored during pharmaceutical ward rounds,and the suspected drugs should be reduced or stopped immediately after the occurrence of drug-induced peripheral neuritis.
万方数据
维普
